Target intelligence / Profile preview

GNAS antisense RNA 1 (GNAS-AS1)

Target
GNAS-AS1
Molecular classification
Long non-coding RNA
01

Overview

GNAS antisense RNA 1 (GNAS-AS1) is a long non-coding RNA (lncRNA) transcribed from the GNAS gene locus on chromosome 20q13.3. It is a paternally-imprinted and antisense transcript to the GNAS gene, which encodes the alpha subunit of the stimulatory G protein. GNAS-AS1 influences the expression of the GNAS complex locus, is involved in the regulation of multiple cellular functions including cell proliferation, apoptosis, and epithelial-mesenchymal transition, and is implicated in the development of a variety of diseases such as cancer (breast, lung, and pituitary), pseudohypoparathyroidism type Ib, McCune-Albright syndrome, and metabolic disorders. GNAS-AS1 exerts its effects primarily through interactions with microRNAs (such as miR-433-3p) and other gene regulatory mechanisms. It is not a classical drug target such as a receptor, enzyme, or transporter, but has significance as a biomarker and regulator of disease pathogenesis.

Other names
GNAS-ASGNAS1ASNCRNA00075NESP-ASNESPASSANGGNASASnon-protein coding RNA 75
02

Mechanism of action

Not a direct drug target; functions by regulating microRNAs (e.g., miR-433-3p), gene expression, and signaling axes such as miR-433-3p/GATA3 and miR-433-3p/Rab3A

03

Biological functions

Regulation of gene expressionRegulation of the GNAS complex locusModulation of cell proliferation and apoptosisPromotion of epithelial-mesenchymal transition (EMT)Promotion of M2 macrophage polarization
04

Disease associations

Cancer (breast cancer, lung adenocarcinoma, prostate cancer, pituitary adenomas)Pseudohypoparathyroidism type IbMcCune-Albright syndromeObesity and metabolic disorders
05

Safety considerations

As a non-coding RNA and regulatory molecule, not directly druggable; manipulation may impact multiple downstream pathways, potentially resulting in off-target effects
06

Biomarkers

Potential biomarker for cancer diagnosis and prognosis, including lung cancer and breast cancer, especially due to its association with cell proliferation and EMT

Beyond the preview

Go deeper on GNAS antisense RNA 1 (GNAS-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNAS antisense RNA 1 (GNAS-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call